Actelion receives Therapeutic Goods Administration (TGA) approval in Australia for Opsumit (macitentan) in Pulmonary Arterial Hypertension (PAH) (Actelion Ltd)

(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 07 February 2014 - Actelion Ltd (SIX: ATLN) today announced the approval of Opsumit® (macitentan) 10 mg for the treatment of pulmonary arterial hypertension (PAH) by the Therapeutic Goods Administration (TGA) of Australia. Opsumit, as monotherapy or in combination with approved PAH treatments (phosphodiesterase-5 inhibitors or inhaled prostanoids), is indicated for the treatment of idiopathic and heritable PAH as well as PAH associated with connective tissue disease and PAH associated with congenital heart disease with repaired shunts in patients with WHO Functional class II,III or IV symptoms. Professor Trevor Williams, Clinical Director...